Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study Of Intravenous DX-8951f (EXATECAN MESYLATE) Administered Daily For Five Days Every Three Weeks To Pediatric And Young Adult Patients With Ewing's Sarcoma (ES), Primitive Neuroectodermal Tumor (PNET), Or Desmoplastic Small Round Cell Tumor (DSRCT)

NCT00055952 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT00055952
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00055952 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study Of Intravenous DX-8951f (EXATECAN MESYLATE) Administered Daily For Five Days Every Three Weeks To Pediatric And Young Adult Patients With Ewing's Sarcoma (ES), Primitive Neuroectodermal Tumor (PNET), Or Desmoplastic Small Round Cell Tumor (DSRCT)
Lead sponsor
Daiichi Sankyo
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2003
Completion date
April 30, 2006
Enrollment
Not reported
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

sarcoma